Search results
Showing 1231 to 1245 of 1254 results for criteria
More people with rare genetic disorder eligible for nusinersen
Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.
More people could be offered genetic testing for genes linked to ovarian cancer
A new draft NICE guideline for inherited ovarian cancer published today (15 September 2023), recommends more people are tested for genes linked to ovarian cancer.
Adapted shoes recommended for people with severe osteoarthritis
People with osteoarthritis who are eligible for knee surgery could be offered specially adapted shoes to help with their painful and stiff knees following a draft recommendation by NICE.
Digital services to enable easier access to weight management support
Four digital programmes can be used to help the NHS deliver specialist weight management services to support the use of medication in England
Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
New price deal paves way for NICE approval of treatment for rare genetic condition
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
Nine treatment options to be made available for adults with depression or an anxiety disorder
Six digitally enabled therapies for adults with anxiety disorders and three for adults with depression have been recommended for use in the NHS.
An early introduction to NICE’s ongoing activity in virtual wards
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment
Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.
Learn more about the proposed changes to our routing criteria for highly specialised technologies
News Podcasts Learn more about the proposed changes to our routing criteria for highly specialised technologies Podcasts 31 December...